This page's job is completeness. Rankings persuade; a directory enumerates. Every company below gets the same 18-field record in our ledger; profile depth and verified dollar figures land as each provider clears verification. Structural facts shown here reflect our latest review and can change — the profile page carries the authoritative dated record.
Sam LLC has a material business relationship with NexLife and earns affiliate commissions from some listed providers. Inclusion in this directory is free and universal; no provider can pay to be added, removed, or reordered. Details.
Flat-rate compounded GLP-1 programs across standard, microdose, and sublingual ODT protocols. Distinguishing structure: dose-flat pricing with a rate lock ("Flat Forever"), $0 membership/consult fees, CARE360 support included, cancel with 30 days' notice. Injectable tirzepatide from $139/mo (12-mo plan); semaglutide from $119/mo. Full profile →
Obesity-medicine telehealth built on a monthly clinical membership plus separately billed medication through partner pharmacies; known for board-certified obesity specialists and an active stance on personalized compounded dosing. Pricing, states, and cancellation terms: pending verification against checkout.
Direct-to-consumer compounded GLP-1 programs with bundled provider access; markets multiple formats including oral options. Formulation sourcing and true-cost fields pending verification.
Large telehealth platform; post-2025 emphasis on FDA-approved brand access (Zepbound, Wegovy — including manufacturer-direct vial integration) with insurance navigation and cash-pay pathways. Strongest fit in our taxonomy: insurance-first candidates.
Mass-market telehealth; weight programs centered on compounded semaglutide offerings and brand pathways, with well-publicized manufacturer-partnership turbulence in 2025. Current formulation lineup and pricing pending verification.
Sister platform to Hims focused on women's health; weight-loss programs with compounded semaglutide and lifestyle support. Fields pending verification.
One of the earliest large compounded-GLP-1 telehealth brands; flat-subscription positioning. Post-shortage formulation strategy and current legal posture: pending verification.
DTC weight-loss telehealth marketing bundled GLP-1 programs. Pharmacy partners and true-cost fields pending verification.
Subscription weight-loss telehealth with compounded GLP-1 offerings. Fields pending verification.
Weight-care platform pairing medication pathways (brand and, historically, compounded) with behavioral programming and insurance navigation. Fields pending verification.
Smaller DTC GLP-1 telehealth brand — exactly the kind of lesser-covered candidate this directory exists to surface. Full record pending verification.
Missing a provider? The directory's usefulness is completeness — submissions welcome via the corrections process on any page. New entries start at "verification queued" like everyone else.
6 questions, 2 minutes, no email collected. If insurance is your best route, the quiz says so.
Find your match →